STOCK TITAN
  1. Home
  2. Sec-filings
  3. MLYS
  4. [Form 4] Mineralys Therapeutics, Inc. Insider Trading Activity

MLYS CEO sells 200,000 shares within $41.0500–$47.4191 range

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) reported insider activity on a Form 4. The company’s Chief Executive Officer and director sold 200,000 shares of common stock on 11/11/2025 in multiple transactions at weighted‑average prices that include $41.6395, $42.3095, $43.4959, $45.2003, $45.8335, and $46.8862. Footnotes disclose execution price ranges spanning $41.0500 to $47.4191 for the respective trades.

After these sales, the reporting person beneficially owns 631,305 shares, held directly. This filing lists the transactions as open‑market sales with weighted‑average pricing and provides to interested parties the availability of detailed trade‑by‑trade breakdowns upon request.

Positive

  • None.

Negative

  • None.

Insights

Insider sold 200,000 MLYS shares; 631,305 remain directly owned.

The filing details open‑market sales by the CEO/director totaling 200,000 shares on 11/11/2025. Trades were reported at weighted‑average prices, with per‑trade ranges disclosed in footnotes, a standard approach for aggregated executions.

Footnotes list execution ranges from $41.0500 to $47.4191, corresponding to tranche averages such as $41.6395 and $46.8862. Following the transactions, direct beneficial ownership is 631,305 shares. Cash‑flow affects the insider; the company’s capital position is not addressed in this report.

As a routine Section 16 disclosure, this is generally neutral for valuation. Actual market impact depends on investor interpretation of insider activity and subsequent company disclosures.

Insider Congleton Jon
Role Chief Executive Officer
Sold 200,000 shs ($9.09M)
Type Security Shares Price Value
Sale Common Stock 12,806 $41.6395 $533K
Sale Common Stock 8,862 $42.3095 $375K
Sale Common Stock 4,000 $43.4959 $174K
Sale Common Stock 29,207 $45.2003 $1.32M
Sale Common Stock 112,275 $45.8335 $5.15M
Sale Common Stock 32,850 $46.8862 $1.54M
Holdings After Transaction: Common Stock — 818,499 shares (Direct)
Footnotes (1)
  1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.0500 to $42.0000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.0500 to $43.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.1700 to $44.0500. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.4800 to $45.4297. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.4300 to $46.4200. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.4400 to $47.4191. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Congleton Jon
(Last) (First) (Middle)
150 N. RADNOR CHESTER ROAD,
SUITE F200
(Street)
RADNOR PA 19087
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/11/2025 S 12,806 D $41.6395(1) 818,499 D
Common Stock 11/11/2025 S 8,862 D $42.3095(2) 809,637 D
Common Stock 11/11/2025 S 4,000 D $43.4959(3) 805,637 D
Common Stock 11/11/2025 S 29,207 D $45.2003(4) 776,430 D
Common Stock 11/11/2025 S 112,275 D $45.8335(5) 664,155 D
Common Stock 11/11/2025 S 32,850 D $46.8862(6) 631,305 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.0500 to $42.0000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.0500 to $43.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.1700 to $44.0500. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.4800 to $45.4297. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
5. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.4300 to $46.4200. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
6. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.4400 to $47.4191. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.
Remarks:
/s/ Adam Levy, Attorney-in-fact 11/13/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many MLYS shares did the CEO sell according to the Form 4?

The CEO/director sold 200,000 shares of Mineralys Therapeutics common stock.

On what date did the MLYS insider transactions occur?

The sales occurred on 11/11/2025.

What were the reported weighted‑average prices for the MLYS sales?

Weighted‑average prices included $41.6395, $42.3095, $43.4959, $45.2003, $45.8335, and $46.8862.

What price ranges did the Form 4 disclose for the MLYS trades?

Footnotes show execution ranges from $41.0500 to $47.4191 for the respective tranches.

How many MLYS shares does the reporting person own after the transactions?

Following the reported sales, the insider beneficially owns 631,305 shares, held directly.

Were the MLYS sales made in multiple transactions?

Yes. The filing reports multiple transactions with weighted‑average prices and provides that detailed breakdowns are available upon request.